Mapping Physiological ADP-Ribosylation Using Activated Ion Electron Transfer Dissociation

Buch-Larsen, Sara C.; Hendriks, Ivo A.; Lodge, Jean M.; Rykaer, Martin; Furtwangler, Benjamin; Shishkova, Evgenia; Westphall, Michael S.; Coon, Joshua J.; Nielsen, Michael L.

Published in:
Cell Reports

DOI:
10.1016/j.celrep.2020.108176

Publication date:
2020

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY-NC-ND

Citation for published version (APA):
Mapping Physiological ADP-Ribosylation Using Activated Ion Electron Transfer Dissociation

Graphical Abstract

Highlights

- AI-ETD proves superior for unbiased proteome-wide analysis of ADP-ribosylation
- Profiling of 5,000 ADPr sites from limited starting material
- Mapping of physiological ADPr sites without perturbation or genetic engineering
- PARP8 and PARP14 are exclusively modified on cysteines and tyrosines, respectively

Authors

Sara C. Buch-Larsen, Ivo A. Hendriks, Jean M. Lodge, ..., Michael S. Westphall, Joshua J. Coon, Michael L. Nielsen

Correspondence

michael.lund.nielsen@cpr.ku.dk

In Brief

Buch-Larsen et al. investigate the ADP-ribosylome in a physiological context by combining AI-ETD with unbiased proteomics enrichment of ADP-ribosylation. The authors demonstrate that physiological ADPr mainly targets serine residues, specifically targets arginine residues in ER and Golgi proteins, and find that PARP8 and PARP14 are exclusively ADP-ribosylated on cysteine and tyrosine residues, respectively.
Mapping Physiological ADP-Ribosylation Using Activated Ion Electron Transfer Dissociation


Resource

ADP-ribosylation (ADPr) is a post-translational modification that plays pivotal roles in a wide range of cellular processes. Mass spectrometry (MS)-based analysis of ADPr under physiological conditions, without relying on genetic or chemical perturbation, has been hindered by technical limitations. Here, we describe the applicability of activated ion electron transfer dissociation (AI-ETD) for MS-based proteomics analysis of physiological ADPr using our unbiased Af1521 enrichment strategy. To benchmark AI-ETD, we profile 9,000 ADPr peptides mapping to >5,000 unique ADPr sites from a limited number of cells exposed to oxidative stress and identify 120% and 28% more ADPr peptides compared to contemporary strategies using ETD and electron-transfer higher-energy collisional dissociation (EThcD), respectively. Under physiological conditions, AI-ETD identifies 450 ADPr sites on low-abundant proteins, including in vivo cysteine modifications on poly(ADP-ribosyl)polymerase (PARP) 8 and tyrosine modifications on PARP14, hinting at specialist enzymatic functions for these enzymes. Collectively, our data provide insights into the physiological regulation of ADPr.

INTRODUCTION

ADP-ribosylation (ADPr) is an emerging post-translational modification (PTM) regulating a variety of biological processes, including cell signaling and DNA damage repair, by modifying proteins with either one ADPr moiety (mono-ADP-ribosylation [MARylation]) or several ADPr moieties (poly-ADP-ribosylation [PARylation]). ADP-ribosyltransferases (ARTs) catalyze the modification by transferring ADPr units from NAD⁺ onto target proteins. The group of responsible enzymes can be divided into two groups depending on the conserved structural features: ARTCs (cholera toxin-like) and ARTDs (diphtheria toxin-like, better known as poly[ADP-ribosyl]polymerases [PARPs]), of which the latter is the largest and most characterized group consisting of 17 members in human (Lüscher et al., 2018). Within the ARTDs, 4 and 12 enzymes are reported to possess PARylation and MARylation activity, respectively, while PARP13 is reported to be catalytic inactive (Lüscher et al., 2018).

The most thoroughly studied PARP enzyme is PARP1, which is predominantly investigated in relation to DNA damage repair (De Vos et al., 2012). Under genotoxic stress, PARP1 modifies serine residues when complexed to the co-factor histone PARylation factor 1 (HPF1) (Bonfiglio et al., 2017b), with this induction abrogated by PARP inhibitors (Larsen et al., 2018). ADPr is a reversible PTM, allowing it to adapt to cellular stimuli in a rapid and temporal manner, with poly(ADP-ribose) glycohydrolase (PARG) being one of the key enzymes degrading PAR chains into MAR (D’Amours et al., 1999).

Mass spectrometry (MS)-based proteomics methods have become the primary approach for studying ADPr in a global and unbiased manner. ADPr modifies proteins at very low levels, making enrichment methods necessary. MS-based analysis is further complicated by the dynamic nature of ADPr, with a rapid enzymatic turnover of the modification (Alvarez-Gonzalez and Althaus, 1989), numerous modifiable amino acid residues (Altmeier et al., 2009; Bonfiglio et al., 2017b; McDonald and Moss, 1994; Moss and Vaughan, 1977; Ogata et al., 1980; Sekine et al., 1989; Van Ness et al., 1980), and the highly labile nature of the modification (Bonfiglio et al., 2017a).

Several methods have been established for enrichment of ADPr-modified peptides for MS analysis (Daniels et al., 2014; Gagne et al., 2018; Hendriks et al., 2019; Larsen et al., 2018; Zhang et al., 2013). For large-scale studies of ADPr, the two most widely used strategies are based either on affinity enrichment using the Af1521 macrodomain or on a combination of boronate-affinity enrichment coupled with chemical conversion of ester-bound ADPr modifications into hydroxamides using hydroxylamine. Whereas the Af1521-based enrichment strategy identifies the entire ADPr moiety on any amino acid residue
Figure 1. Comparison of AI-ETD versus ETD and ETHcD for Mapping ADP-Ribosylation

(A) Overview of the strategy employed to enrich ADPr peptides. All samples were analyzed in technical quadruplicate; n = 4.

(B) Overview of the number of ADPr peptide-spectrum matches (PSMs) identified and localized (>90% probability) for each dissociation method and supplemental activation energy (SAE; laser power for AI-ETD, normalized collision energy for ETHcD). Significance was determined using two-tailed Student’s t testing. Error bars represent SD; n = 4 technical replicates.

(C) As in (B), but displaying the number of ADPr sites identified.

(legend continued on next page)
(Larsen et al., 2018), the chemical-based strategy identifies chemical marks only on aspartate and glutamate residues as a trace of ADPr (Li et al., 2019; Zhang et al., 2013). Moreover, although Af1521 is capable of identifying ADPr under endogenous conditions, knockdown of PARG is required to increase sensitivity for the chemical-based method, rendering investigation of ADPr under physiological conditions impossible (Li et al., 2019; Zhang et al., 2013).

We previously demonstrated that tandem MS acquisition relying on beam-type collisional activation (e.g., higher-energy collisional dissociation [HCD]) cannot be used for confidently localizing ADPr sites because of the labile nature of the bond between the modification and the amino acid residue (Larsen et al., 2018). However, the non-ergodic fragmentation propensity of the radical-driven electron transfer dissociation (ETD) methodology preserves labile PTMs and can thus allow confident determination of the exact amino acid residue being modified with ADPr. Electron transfer reactions, however, often result in non-dissociative electron transfer (ETnoD), especially for precursors with low mass-to-charge ratio like ADPr-modified peptides (Larsen et al., 2018; Ledvina et al., 2010). To overcome the high degree of ETnoD, supplemental activation can be applied with electron-transfer higher-energy collisional dissociation (EThCD), which has been proved to be more effective than ETD for identification of ADPr sites (Bilan et al., 2017; Hendriks et al., 2019). However, despite that EThCD utilizes supplementary activation in order to counter ETnoD, this effect did not improve dissociation of charge-reduced product ions resulting from fragmentation of ADPr peptides (Hendriks et al., 2019).

By contrast, activated ion ETD (AI-ETD) uses infrared photoactivation during the ETD reaction to disrupt the gas-phase non-covalent interactions that prevent formation of c and z-type product ions, thereby greatly reducing ETnoD. This benefits glycoproteomics (Riley et al., 2019), top-down proteomics (McCool et al., 2019; Riley et al., 2018a, 2018b), and phosphoproteomics (Riley et al., 2017a). We therefore set out to investigate the utility of AI-ETD for identification and confident localization of ADPr sites. Here, AI-ETD proved advantageous for analyzing ADPr-enriched samples, with AI-ETD mapping 79% and 23% more ADPr sites compared with ETD and EThCD, respectively. This allowed us to obtain a comparable depth of sequencing from markedly less input material and enabled identification of 450 physiological ADPr sites, of which 60% were not previously identified under physiological conditions. Taken together, we demonstrate that AI-ETD is a superior dissociation technique for analysis of ADPr.

 RESULTS

Evaluation of AI-ETD

To investigate the ability of AI-ETD to increase dissociation of ADPr peptides, we utilized our established Af1521 method for efficient and high-purity enrichment of peptides modified by ADPr (Figure 1A). Because the binding affinity of the macrodomain is toward the terminal moiety of ADP-ribose (Karras et al., 2005), the Af1521 strategy is capable of detecting modification of any amino acid residue type by ADPr (Larsen et al., 2018).

For the purpose of initial optimization and direct comparison of AI-ETD with other dissociation methodologies, we purified ADPr peptides from H2O2-treated HeLa cells, because H2O2 is known to induce ADPr via activation of PARP1 and PARP2. This sample was used as a technical standard for quadruplicate comparison of different dissociation types, with each experiment corresponding to a comparatively low amount of ADPr peptides purified from only two million cells. We compared standard ETD and EThCD with AI-ETD at five different laser power (LP) settings spanning the range of routinely used power settings (Ledvina et al., 2010; Riley et al., 2017b).

We observed a higher number of identified and localized unique modified ADPr peptides for all five AI-ETD LP settings, compared with ETD (Figure 1B; Table S1A). The optimum was 20% LP, with a gradual falloff in identification rate for both lower and higher LP. AI-ETD identified 120% and 28% more ADPr peptides than ETD and EThCD, respectively. When considering the number of unique ADPr sites on proteins, we found the same trend (Figure 1C; Table S2A), with AI-ETD mapping 79% and 23% more sites compared with ETD and EThCD, respectively.

In terms of spectral quality, AI-ETD demonstrated the highest scores at relatively low LP, with an optimum at 15% (Figure 1D). Using 25% LP and above, or EThCD, resulted in a decline in spectral quality, suggesting excessive peptide fragmentation under these circumstances. When considering localization of the ADP-ribose to specific amino acid residues, we found that on average AI-ETD at 15% and 20% LP and EThCD significantly outperformed ETD (Figure 1E). However, when filtering ADPr for a stringent (>90%) localization, AI-ETD at 20% LP was superior.

Previously, we demonstrated complementarity of trypsin and Lys-C digestions for identification of unique ADPr sites (Hendriks et al., 2019). Thus, we purified ADPr peptides as described above, but using Lys-C instead of trypsin digestion. We subjected these peptides to technical quadruplicate analysis with a similar experimental setup, using the three optimal AI-ETD LP settings. Overall, the aforementioned findings could be recapitulated, with the best performance of AI-ETD at 20% LP,
identifying 134% and 30% more ADPr peptides than ETD and EThcD, respectively (Figure S1A; Table S1A). At the site-specific level, AI-ETD mapped 118% and 28% more ADPr sites than ETD and EThcD, respectively (Figure S1B; Table S2A), and spectral quality was likewise improved by AI-ETD (Figure S1C).

Based on these observations, we wondered whether the enhanced performance of AI-ETD resulted from increased dissociation of reduced charge-state precursors, i.e., decreased levels of ETnO-D and an overall more complete fragmentation of the ADPr peptides. Intriguingly, AI-ETD considerably reduced levels of ETnO-D and an overall more complete fragmentation of ADPr peptides. Overall, AI-ETD reduced ETnO-D to practically zero at the highest LP (Figure 1F), whereas EThcD failed to resolve ETnO-D product ions to the same extent. Concomitantly, unmodified peptides within the same samples were only modestly affected by AI-ETD, because these were generally short peptides that did not display high levels of ETnO-D to start with. This highlights a striking susceptibility of ADPr peptides to AI-ETD, with a notably increased fragmentation of ADPr peptides at higher AI-ETD LP compared with unmodified peptides (Figure 1G; Figure S1E). In contrast, EThcD did not greatly or explicitly increase fragmentation of ADPr peptides. Overall, AI-ETD reduced ETnO-D and led to more complete fragmentation of ADPr peptides specifically.

Whereas AI-ETD at the highest LP greatly fragmented ADPr peptides, it did not result in the highest number of identifications. To investigate this, we compared the degree of peptide fragmentation with spectral score. For unmodified peptides, higher degrees of fragmentation globally correlated to higher spectral quality (Figure S1F). For localized ADPr peptides, the highest quality spectra resided between 30% and 45% fragmentation, with a strong decline in spectral quality when fragmentation exceeded 50% (Figure 1H). Indeed, when considering identified but non-localized ADPr peptides, a considerably higher number of these were >50% fragmented (Figure S1G), suggesting that very high degrees of ADPr peptide fragmentation are detrimental to faithful identification and localization. Collectively, we show that AI-ETD is superior to ETD and EThcD for confident profiling of ADPr sites.

**Benchmarking AI-ETD for In-Depth Profiling of ADPr**

To gauge the performance of AI-ETD in the context of deep analysis of the ADP-ribosylome, we employed our previously described high-pH fractionation on ADPr peptides purified from H2O2-treated HeLa cells (Hendriks et al., 2019; Larsen et al., 2018), using AI-ETD at the optimal 20% LP for all further experiments. Additionally, to address the large amount of starting material usually required for proteomic profiling of ADPr (Abplanalp et al., 2017; Hendriks et al., 2019; Larsen et al., 2018; Li et al., 2019; Zhang et al., 2013), we used a considerably smaller amount of sample. In total, 8,939 unique ADPr peptides were identified (Table S1B), mapping to 5,206 confidently localized ADPr sites (Figure 2A; Table S2B). Compared with previous studies, the identified number of ADPr sites fell just short of the current single-study record of 7,000 (Hendriks et al., 2019). Nevertheless, the relative amount of input material analyzed here was only ~20%, yet still facilitated identification of ~75% of the total number of sites (Figure 2A). Additionally, our AI-ETD profiling of the ADP-ribosylome from limited input revealed 1,800 ADPr target proteins (Table S3), corresponding to 84% of identifications from the largest study to date (Hendriks et al., 2019). Over half of the ADPr target proteins were modified on two or more distinct ADPr sites, demonstrating deep coverage of this low-stoichiometry PTM (Figure S2).
Figure 3. Analysis of Physiological ADPr Using Al-ETD

(A) Overview of the number of physiological ADPr sites identified in this study, compared with a previous study that also included physiological ADPr (Larsen et al., 2018). Total: unique ADPr sites identified across all four cell culture replicates; Best rep.: unique ADPr sites identified in the best replicate; SS: single-shot analysis; All: high-pH fractionated analysis.

(B) Left: pie chart overview of the numerical amino acid residue distribution of all physiological ADPr sites identified in this study. Right: scaled Venn diagram visualizing distribution of identified physiological ADPr sites in this study compared with our previous study (Larsen et al., 2018).

(C) Average localization probability across all ADPr PSMs that were at least partially localized (>51%) to each specific amino acid residue type. Only amino acids with >10 partially localized PSMs were included. Error bars represent SEM; number of data points (n) is indicated.

(D) Depth of sequencing analysis, plotting number of identified physiological ADPr target proteins versus their known copy numbers. Proteins ADP-ribosylated in response to H2O2 were derived from this study, as well as various other studies (Bilan et al., 2017; Jungmichel et al., 2013; Larsen et al., 2018; Martello et al., 2016; Zhang et al., 2013). Protein copy numbers were derived from a deep HeLa proteome study (Bekker-Jensen et al., 2017), which covers the vast majority (>99%) of all ADPr target proteins identified. Dotted lines with color indicator below represent the median protein copy number for ADPr target proteins within each respective subset.

(E) “Fidget spinner” analysis, composed of scaled Venn diagram (center) visualizing distribution of H2O2-induced and physiological ADPr sites; pie chart overviews (around the center) of the amino acid residue distribution of each subset of ADPr sites, as indicated by background coloring; term enrichment analyses (legend continued on next page)
Overall, 1,798 (35%) and 2,045 (39%) sites were previously described by either or both of our other studies, respectively (Figure 2B). Moreover, we identified 1,383 (26%) previously undescribed ADPr sites (Table S4). We observed the large majority of modification to occur on serine residues (83%), followed by modification of arginine (5.9%), histidine (4.5%), and tyrosine (2.8%) residues (Figure 2C, left). Considering the subset of ADPr sites exclusively identified in this study, the majority of these still resided on serine residues (58%), but with a relatively larger fraction of ADPr targeting arginine (17%), histidine (8.7%), tyrosine (4.8%), lysine (4.7%), cysteine (3.2%), threonine (2.1%), aspartate (1.1%), and glutamate (0.7%) residues (Figure 2C, right).

The H2O2-induced ADP-ribosylome profiled using AI-ETD largely resided on proteins with functional annotations that are well-known in the context of ADPr biology (Figure 2D; Table S5A). Taken together, AI-ETD is congruous with deep analysis of the ADP-ribosylome from a limited pool of starting material.

**Improved Analysis of Physiological ADPr Using AI-ETD**

ADPr is frequently investigated in a non-physiological manner, e.g., by genetic perturbation of ADP eraser enzymes (Daniels et al., 2014; Zhang et al., 2013) or by exposure of cells to high levels of stress, which both boost cellular levels of ADPr to facilitate detection. Levels of ADPr are >30-fold lower under physiological conditions (Larsen et al., 2018), which makes physiological ADPr technically challenging to study, despite the biomedical importance of elucidating how ADPr is regulated in, e.g., clinical samples or patient biopsies. Therefore, we set out to evaluate the ability of AI-ETD to profile the physiological ADP-ribosylome.

We purified ADPr-modified peptides from unperturbed HeLa cells growing under standard conditions, and minimized MS machine time by performing single-shot analyses. In total, we identified 703 unique ADPr peptides, corresponding to 450 ADPr sites residing on 295 proteins (Figure 3A). We identified up to 79% more ADPr sites compared with our previous study (Larsen et al., 2018) and up to 387 physiological ADPr sites in 50 min (i.e., 8 sites/min) of MS time.

Of the 450 physiological ADPr sites we identified, 286 (64%) were not previously mapped under unperturbed conditions (Figure 3B, right), and 70 were not at all found in proteomics screens (Table S4). Intriguingly, serine residues (55%) remained the most commonly ADP-ribosylated under physiological conditions (Figure 3B, left). Nonetheless, we also observed frequent modification of arginine (26%), histidine (12%), and cysteine (3.3%) residues. In terms of total modification abundance, we observed 86.6%, 9.5%, and 2.5% of all physiological ADPr to reside on serine, arginine, and histidine residues, respectively (Figure S3A). Physiological ADPr could be confidently localized on cysteine, histidine, arginine, serine, threonine, and tyrosine residues (Figure 3C), although we did not observe consistent ADPr of lysine, glutamate, and aspartate residues. Under physiological conditions, >50% of serine ADPr resided in lysine-serine (KS) motifs (Figure S3B), an established phenomenon for serine ADPr (Larsen et al., 2018). Adherence to KS motifs was considerably lower in response to oxidative stress (Figure S3B), suggesting that under these conditions serine residues may be targeted more promiscuously. Physiological ADPr predominantly targeted nuclear proteins (71%; Figure S3C), although not to the same extent as H2O2-induced ADPr (85%; Figure S3D).

Next, we investigated the expression levels of ADPr target proteins (Figure 3D). With inclusion of H2O2-induced ADPr, protein copy numbers of ADPr target proteins spanned six orders of magnitude. Physiological ADPr target proteins identified here covered a somewhat lower range of expression levels. Nonetheless, compared with physiological ADPr target proteins identified in our previous study (Larsen et al., 2018), we achieved a 57% greater depth of sequencing (Figure 3D).

Combining previous proteomics-based knowledge on ADPr (Bilan et al., 2017; Bonfiglio et al., 2017b; Hendriks et al., 2019; Larsen et al., 2018) with the additional insight gained in this study, we set out to investigate systemic differences between physiological and H2O2-perturbed ADPr biology. Specifically, we compared 9,029 H2O2 ADPr sites with 643 physiological ADPr sites (Figure 3E) and found the vast majority of ADPr sites (93%) were exclusive to H2O2 treatment, 6% of ADPr sites were detected in both cases, and 1% of ADPr sites were exclusive to physiological conditions. In terms of amino acid distribution, H2O2-exclusive ADPr predominantly modified serine residues (84%), in agreement with previous reports (Hendriks et al., 2019; Larsen et al., 2018; Palazzo et al., 2018). ADPr detected under all conditions still targeted a majority of serine residues (82%), but moreover modified significant fractions of arginine (13%), histidine (13%), cysteine (5%), and lysine (4%) residues. Intriguingly, physiologically exclusive ADPr primarily modified arginine residues (66%), with further modification of histidine (15%) and cysteine (10%) residues, and only a small fraction of modification on serine residues (5.7%). Overall, our data reveal a propensity for ADPr to be targeted to different amino acid residues dependent on cellular conditions.

Next, we assessed the relative differences between physiological and non-physiological ADPr (Figure 3E; Table S5B). H2O2-specific ADPr was more frequently observed to target proteins involved in RNA-binding, DNA replication, and cell cycle. Physiologically specific ADPr preferentially targeted proteins with sulfotransferase activity, glycoproteins, and membrane proteins. Finally, proteins ADP-ribosylated under all conditions represented terms canonically associated with ADPr, including predominant modification of the ADP enzymatic machinery, histone proteins, and DNA repair proteins. Collectively, our comparison between physiological and H2O2-induced ADPr demonstrates a considerable shift in the targeting of this PTM, not only at the substrate level, but also in terms of which amino acid residue types are modified.

(outermost graphs) using Gene Ontology annotations and UniProt keywords, comparing proteins identified to be ADP-ribosylated in each subset of ADPr sites as compared with the other subsets, indicated by background coloring. Relative score is based on multiplication of logarithms derived from the enrichment ratio and the q value. Terms were significant with q < 0.02, as determined by Fisher exact testing with Benjamini-Hochberg correction. The full-term enrichment analysis is available in Table S5B. Background and Venn coloring: red, H2O2 only; purple, both H2O2 and physiological; blue, physiological only.
<table>
<thead>
<tr>
<th>Gene Name</th>
<th>AA</th>
<th>Intensity</th>
<th>No. of Sites</th>
<th>Primary ADPr</th>
<th>Fraction</th>
<th>Secondary ADPr</th>
<th>Fraction</th>
<th>Tertiary ADPr</th>
<th>Fraction</th>
<th>GOBP</th>
<th>GOCC</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARP1</td>
<td>S</td>
<td>1.1E+10</td>
<td>11</td>
<td>S-499</td>
<td>67.1%</td>
<td>S-507</td>
<td>27.7%</td>
<td>S-519</td>
<td>4.3%</td>
<td>ADP-ribosylation</td>
<td>nucleus</td>
</tr>
<tr>
<td>Histone H2B*</td>
<td>S</td>
<td>8.8E+9</td>
<td>8</td>
<td>S-7</td>
<td>99.1%</td>
<td>R-80</td>
<td>0.6%</td>
<td>S-15</td>
<td>0.3%</td>
<td>nucleosome</td>
<td>chromosome</td>
</tr>
<tr>
<td>Histone H3*</td>
<td>S</td>
<td>7.7E+9</td>
<td>2</td>
<td>S-11</td>
<td>87.6%</td>
<td>S-29</td>
<td>12.4%</td>
<td></td>
<td></td>
<td>nucleosome</td>
<td>chromosome</td>
</tr>
<tr>
<td>NPM1</td>
<td>S</td>
<td>1.2E+9</td>
<td>8</td>
<td>S-207</td>
<td>48.1%</td>
<td>S-139</td>
<td>26.3%</td>
<td>S-195</td>
<td>11.3%</td>
<td>cell cycle</td>
<td>nucleus</td>
</tr>
<tr>
<td>HIST1H4A</td>
<td>S</td>
<td>1.1E+9</td>
<td>2</td>
<td>S-2</td>
<td>99.5%</td>
<td>S-48</td>
<td>0.5%</td>
<td></td>
<td></td>
<td>nucleosome</td>
<td>chromosome</td>
</tr>
<tr>
<td>HNRNPu</td>
<td>S</td>
<td>5.4E+8</td>
<td>2</td>
<td>S-187</td>
<td>98.6%</td>
<td>S-695</td>
<td>1.4%</td>
<td></td>
<td></td>
<td>mRNA processing</td>
<td>nucleus</td>
</tr>
<tr>
<td>NOLC1</td>
<td>S</td>
<td>3.5E+8</td>
<td>6</td>
<td>S-303</td>
<td>78.2%</td>
<td>S-580</td>
<td>19.8%</td>
<td>S-508</td>
<td>1.1%</td>
<td>cell cycle</td>
<td>nucleolus</td>
</tr>
<tr>
<td>HIST1H1E</td>
<td>S</td>
<td>2.5E+8</td>
<td>3</td>
<td>S-150</td>
<td>68.6%</td>
<td>S-55</td>
<td>26.5%</td>
<td>S-27</td>
<td>4.9%</td>
<td>nucleosome</td>
<td>chromosome</td>
</tr>
<tr>
<td>RFC1</td>
<td>S</td>
<td>2.1E+8</td>
<td>6</td>
<td>S-1126</td>
<td>48.1%</td>
<td>S-302</td>
<td>34.1%</td>
<td>S-384</td>
<td>6.6%</td>
<td>DNA replication</td>
<td>nucleus</td>
</tr>
<tr>
<td>WDHD1</td>
<td>S</td>
<td>1.2E+8</td>
<td>3</td>
<td>S-942</td>
<td>83.6%</td>
<td>S-900</td>
<td>10.0%</td>
<td>S-946</td>
<td>6.4%</td>
<td>DNA replication</td>
<td>nucleus</td>
</tr>
<tr>
<td>P4HB</td>
<td>R</td>
<td>1.2E+9</td>
<td>1</td>
<td>R-97</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>isomerase</td>
<td>ER</td>
</tr>
<tr>
<td>PDIa3</td>
<td>R</td>
<td>5.9E+8</td>
<td>1</td>
<td>R-62</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>isomerase</td>
<td>ER</td>
</tr>
<tr>
<td>ASPH</td>
<td>R</td>
<td>5.2E+8</td>
<td>1</td>
<td>R-437</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>hydrolase</td>
<td>ER</td>
</tr>
<tr>
<td>GALNT2</td>
<td>R</td>
<td>2.1E+8</td>
<td>6</td>
<td>R-93</td>
<td>59.4%</td>
<td>R-128</td>
<td>17.9%</td>
<td>R-113</td>
<td>10.7%</td>
<td>glycosyltransferase</td>
<td>Golgi</td>
</tr>
<tr>
<td>TXNDC5</td>
<td>R</td>
<td>1.5E+8</td>
<td>1</td>
<td>R-394</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>isomerase</td>
<td>ER</td>
</tr>
<tr>
<td>PTPRG</td>
<td>R</td>
<td>1.4E+8</td>
<td>1</td>
<td>R-311</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>hydrolase</td>
<td>membrane</td>
</tr>
<tr>
<td>GOLIM4</td>
<td>R</td>
<td>1.2E+8</td>
<td>2</td>
<td>R-110</td>
<td>66.3%</td>
<td>R-445</td>
<td>33.7%</td>
<td></td>
<td></td>
<td>transport</td>
<td>Golgi</td>
</tr>
<tr>
<td>PDIa6</td>
<td>R</td>
<td>1.0E+8</td>
<td>3</td>
<td>R-142</td>
<td>55.2%</td>
<td>R-235</td>
<td>41.0%</td>
<td>R-153</td>
<td>3.8%</td>
<td>isomerase</td>
<td>ER</td>
</tr>
<tr>
<td>PIgS</td>
<td>R</td>
<td>9.5E+7</td>
<td>1</td>
<td>R-176</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>transamidase</td>
<td>ER</td>
</tr>
<tr>
<td>B2M</td>
<td>R</td>
<td>8.7E+7</td>
<td>1</td>
<td>R-32</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>immunity</td>
<td>secreted</td>
</tr>
<tr>
<td>HMGB1</td>
<td>H</td>
<td>2.4E+8</td>
<td>2</td>
<td>H-117</td>
<td>99.8%</td>
<td>S-181</td>
<td>0.2%</td>
<td></td>
<td></td>
<td>DNA repair</td>
<td>nucleus</td>
</tr>
<tr>
<td>CPSF6</td>
<td>H</td>
<td>1.2E+8</td>
<td>1</td>
<td>H-478</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>mRNA processing</td>
<td>nucleus</td>
</tr>
<tr>
<td>PCMT1</td>
<td>H</td>
<td>1.0E+8</td>
<td>1</td>
<td>H-15</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>methyltransferase</td>
<td>cytoplasm</td>
</tr>
<tr>
<td>PPIA</td>
<td>H</td>
<td>6.9E+7</td>
<td>3</td>
<td>H-126</td>
<td>83.1%</td>
<td>C-52</td>
<td>15.4%</td>
<td>R-148</td>
<td>1.4%</td>
<td>isomerase</td>
<td>cytoplasm</td>
</tr>
<tr>
<td>PHIP</td>
<td>H</td>
<td>5.4E+7</td>
<td>1</td>
<td>H-779</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>insulin signaling</td>
<td>nucleus</td>
</tr>
<tr>
<td>FAM118B</td>
<td>H</td>
<td>3.6E+7</td>
<td>1</td>
<td>H-105</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cajal body</td>
<td>nucleus</td>
</tr>
<tr>
<td>XRCC5</td>
<td>H</td>
<td>3.0E+7</td>
<td>1</td>
<td>H-152</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DNA repair</td>
<td>chromosome</td>
</tr>
<tr>
<td>CAMSAP2</td>
<td>H</td>
<td>2.7E+7</td>
<td>1</td>
<td>H-24</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>microtubule</td>
<td>Golgi</td>
</tr>
<tr>
<td>CELF1</td>
<td>H</td>
<td>2.6E+7</td>
<td>1</td>
<td>H-89</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>mRNA processing</td>
<td>nucleus</td>
</tr>
<tr>
<td>MARF1</td>
<td>H</td>
<td>2.0E+7</td>
<td>1</td>
<td>H-1205</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>differentiation</td>
<td>peroxosome</td>
</tr>
<tr>
<td>GMDS</td>
<td>C</td>
<td>1.2E+8</td>
<td>1</td>
<td>C-8</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>dehydratase</td>
<td>cytoplasm</td>
</tr>
<tr>
<td>NSUN2</td>
<td>C</td>
<td>1.1E+8</td>
<td>1</td>
<td>C-271</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>methyltransferase</td>
<td>mitochondrion</td>
</tr>
<tr>
<td>PARP8</td>
<td>C</td>
<td>2.3E+7</td>
<td>3</td>
<td>C-376</td>
<td>46.1%</td>
<td>C-395</td>
<td>39.4%</td>
<td>C-332</td>
<td>14.4%</td>
<td>ADP-ribosylation</td>
<td>ER</td>
</tr>
<tr>
<td>ASCC3</td>
<td>C</td>
<td>1.3E+7</td>
<td>1</td>
<td>C-208</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>hydrolase</td>
<td>nucleus</td>
</tr>
<tr>
<td>NUMA1</td>
<td>C</td>
<td>5.5E+6</td>
<td>2</td>
<td>C-2009</td>
<td>71.7%</td>
<td>H-1689</td>
<td>28.3%</td>
<td></td>
<td></td>
<td>cell cycle</td>
<td>nucleus</td>
</tr>
<tr>
<td>AP1G1</td>
<td>C</td>
<td>3.3E+6</td>
<td>1</td>
<td>C-539</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>transport</td>
<td>Golgi</td>
</tr>
<tr>
<td>TXN</td>
<td>C</td>
<td>9.9E+5</td>
<td>1</td>
<td>C-73</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>transport</td>
<td>mitochondrion</td>
</tr>
<tr>
<td>NONO</td>
<td>C</td>
<td>7.6E+5</td>
<td>1</td>
<td>C-145</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>mRNA processing</td>
<td>nucleus</td>
</tr>
<tr>
<td>GSTM3</td>
<td>C</td>
<td>7.6E+5</td>
<td>1</td>
<td>C-190</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>transferase</td>
<td>cytoplasm</td>
</tr>
<tr>
<td>PEX3</td>
<td>Y</td>
<td>1.4E+7</td>
<td>1</td>
<td>Y-56</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>peroxisome</td>
<td>peroxisome</td>
</tr>
<tr>
<td>PARP14</td>
<td>Y</td>
<td>1.2E+7</td>
<td>3</td>
<td>Y-895</td>
<td>51.1%</td>
<td>Y-1088</td>
<td>27.0%</td>
<td>Y-59</td>
<td>21.9%</td>
<td>ADP-ribosylation</td>
<td>nucleus</td>
</tr>
<tr>
<td>RPS3A</td>
<td>Y</td>
<td>2.0E+6</td>
<td>1</td>
<td>Y-155</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>differentiation</td>
<td>nucleus</td>
</tr>
</tbody>
</table>

A listing of the top 10 physiological ADPr target proteins mainly modified (>2/3rd intensity) on specific amino acid residue types. Only 9 and 3 proteins were mainly modified on cysteine and tyrosine, respectively. Residue types with less than 5 total ADPr sites were excluded. The top 3 most abundant ADPr sites are indicated. Multiple variants of the same histone type were merged, indicated with an asterisk (*). AA, main modified residue type; fraction, relative contribution of this ADPr site to the total ADPr modification of the protein; GOBP, Gene Ontology Biological Process; GOCC, Gene Ontology Cellular Compartment.
Investigation of Residue-Specific Physiological ADP-ribosylation

We constructed a database containing all 385 proteins that are ADP-ribosylated under physiological conditions (Table S6), based upon physiological ADP-ribosylation target proteins identified here and existing proteomics evidence (Larsen et al., 2018). Within this database, we investigated which proteins were predominantly modified on distinct amino acid residue types (Table 1). In line with previous reports (Hendriks et al., 2019; Larsen et al., 2018; Palazzo et al., 2018), proteins primarily ADP-ribosylated on serine residues were nucleus-localized or chromatin-centric proteins with functions in chromosome organization, DNA replication, and cell-cycle regulation, despite their ADP-ribose being observed under physiological conditions. In contrast, proteins mainly modified on arginine residues had enzymatic functions, including isomerase and hydrolase activity, and were largely localized to the endoplasmic reticulum (ER) and the Golgi apparatus. Proteins physiologically modified on histidine, cysteine, or tyrosine residues did not show a particular trend in their annotated biological process or cellular compartment.

Within the 51 proteins exclusively found to be ADP-ribosylated under physiological conditions (Figure 4A; Table S6), only one protein was observed to be modified on a serine residue. Strikingly, 36 of these proteins were solely modified on arginine residues, suggesting a potential downregulation of the arginine ADP-ribose pathway in response to oxidative stress. To gain more insight into their biological interconnectivity and functionality, we performed STRING network analysis on all proteins with a predominant arginine ADP-ribose (Figure 4B). The majority (76%) of these physiological ADP-ribose target proteins were interconnected, with a protein-protein interaction enrichment p value of $1.0 \times 10^{-16}$.

Figure 4. Analysis of Arginine-Specific ADP-Ribosylation

(A) Pie chart of the amino acid residue distribution of ADP-ribose target proteins exclusively modified under physiological conditions.

(B) STRING network visualizing functional interactions between proteins exclusively ADP-ribosylated on arginine residues. Default STRING clustering confidence was used (p > 0.4), and disconnected proteins were omitted from the network unless they were identified by 2+ ADP-ribose sites. Proteins were significantly interconnected, with a protein-protein interaction enrichment p value of $1.0 \times 10^{-16}$.

(C) Distribution of the number of N-linked glycosylation sites per protein, as derived from a composite study (Sun et al., 2019). Line limit, 95th percentile; box limits, 3rd and 1st quartiles; black bar, median; blue bar, average. Number of data points (n) is visualized below the distributions. Significance was determined using two-tailed Student’s t testing.

ER, endoplasmic reticulum; Glyco, glycoprotein; Golgi, Golgi apparatus.

Investigation of Residue-Specific Physiological ADP-ribose Pathway

We constructed a database containing all 385 proteins that are ADP-ribose modified under physiological conditions (Table S6), based upon physiological ADP-ribose target proteins identified here and existing proteomics evidence (Larsen et al., 2018). Within this database, we investigated which proteins were predominantly modified on distinct amino acid residue types (Table 1). In line with previous reports (Hendriks et al., 2019; Larsen et al., 2018; Palazzo et al., 2018), proteins primarily ADP-ribosylated on serine residues were nucleus-localized or chromatin-centric proteins with functions in chromosome organization, DNA replication, and cell-cycle regulation, despite their ADP-ribose being observed under physiological conditions. In contrast, proteins mainly modified on arginine residues had enzymatic functions, including isomerase and hydrolase activity, and were largely localized to the endoplasmic reticulum (ER) and the Golgi apparatus. Proteins physiologically modified on histidine, cysteine, or tyrosine residues did not show a particular trend in their annotated biological process or cellular compartment.

Within the 51 proteins exclusively found to be ADP-ribosylated under physiological conditions (Figure 4A; Table S6), only one protein was observed to be modified on a serine residue. Strikingly, 36 of these proteins were solely modified on arginine residues, suggesting a potential downregulation of the arginine ADP-ribose pathway in response to oxidative stress. To gain more insight into their biological interconnectivity and functionality, we performed STRING network analysis on all proteins with a predominant arginine ADP-ribose (Figure 4B). The majority (76%) of these physiological ADP-ribose target proteins were interconnected and frequently localized to either the ER (47%, p = 2.1 × 10^{-12}) or...
Figure 5. ADP-Ribosylation of Different PARP Family Members

(A) Overview of the most abundantly ADP-modified residues within PARP family members, as a fraction of total protein ADP modification, either under physiological conditions (Phys.) or in response to H$_2$O$_2$. All physiologically detected ADP sites, or otherwise up to four of the most abundant total ADP sites, are indicated on the graphical representation of the PARP family members. Blue lines, physiological ADP sites; red lines, H$_2$O$_2$-induced ADP sites.

(B) Overview of the total amount of ADP detected on each PARP family member, in relation to their known expression level (IBAQ). Both axes are logarithmic, and graph scaling was normalized to PARP1 and PARP2 values.

(C) STRING network visualizing functional interactions between proteins identified to be ADP modified on cysteine residues in this study or in our previous study (Larsen et al., 2018). Default STRING clustering confidence was used (p > 0.4), and disconnected proteins were omitted from the network. Proteins were significantly interconnected, with a protein-protein interaction enrichment p value of 1.1 x 10$^{-11}$. Distribution of color is relative to the number of sites within each category; sites detected both physiologically and in response to H$_2$O$_2$ were colored as physiological.

Cys, modification on cysteine residues; other, modification on non-cysteine residues.
the Golgi (36%, \( p = 5.2 \times 10^{-15} \)). Intriguingly, 80% of the arginine ADPr-modified proteins were also annotated as glycoproteins, representing a highly significant enrichment (\( p = 1.8 \times 10^{-15} \)), in agreement with site-specific analysis (Figure 3E). To further investigate a potential overlap in protein targets of arginine ADPr and glycosylation, we performed a comparison of our physiological ADPr data with a recent complement of N-linked glycosylation proteomics data (Table S6) (Sun et al., 2019). In total, 166 physiological ADPr target proteins were found to also be targeted by N-glycosylation. We observed that for proteins predominantly ADP-ribosylated on arginine residues, the propensity for these proteins to also be N-glycosylation targets was significantly greater as compared with all other physiological ADPr target proteins (Figure 4C), hinting at the existence of crosstalk between arginine ADPr and N-glycosylation.

Overall, our database with physiological ADPr target proteins comprises a vast proteomics resource, underlining a significant presence of serine ADPr even in unperturbed cell systems, while concomitantly highlighting potential spatial preferences for physiological ADPr focused on other residue types.

**Detection of PARP8 and PARP14 Modification in Cells**

PARP1 modifies itself in response to DNA binding (Bolderson et al., 2019), and our physiological profiling corroborated the main modification of PARP1 to target three serine residues (S499, S507, and S519) located in the auto-modification domain of the enzyme (Figure 5A; Table 1).

Based on deep proteomic profiling of HeLa cells, 10 PARP family members are expressed at different levels in unperturbed HeLa cells (Bekker-Jensen et al., 2017). Using AI-ETD, we could detect ADPr modification of PARP1, PARP2, PARP8, PARP12, and PARP14 (Figure 5B; Tables S3 and S4). Strikingly, even though protein copy numbers of PARP8 and PARP14 are 250–500 times lower than PARP1, we could still detect their ADPr under physiological conditions (Table 1).

On PARP2, we observed modification of only serine residues, similar to PARP1 (Figure 5A), corroborating the known inter-connected functions of the two enzymes (Ménissier de Murcia et al., 2003; Schreiber et al., 2002). ADPr on PARP12 was found only in response to H2O2 treatment and at relatively low abundance. Intriguingly, PARP8 was ADP-ribosylated on three cysteine residues (C332, C376, and C395) under physiological conditions (Table 1; Table S2C; Data S1), whereas a fourth cysteine residue (C367) was modified in response to H2O2. This exclusive modification on cysteine residues could hint at PARP8 auto-modification, implying that PARP8 is capable of ADP-ribosylating cysteine residues. Analogously, we observed physiological modification of three tyrosine residues (Y59, Y895, and Y1088) in PARP14 (Table 1; Table S2C; Data S1), which could likewise imply auto-modification and a potential function of PARP14 as the catalyst for tyrosine ADPr.

We were intrigued by the ADPr modification of cysteine residues, with PARP8 modified on four cysteine residues, and knowledge regarding cysteine ADPr being relatively sparse. Altogether, we could map 123 cysteine ADPr sites to 112 proteins (Tables S3 and S4), and generated an interconnected STRING network based on all proteins with cysteine ADPr (Figure 5C). 85 out of 112 proteins (76%) were connected to the network, with significant (\( p = 1.1 \times 10^{-11} \)) enrichment for protein-protein interactions. Beyond PARP8, cysteine ADPr modification occurred on a considerable number of interconnected catalytic ADPr enzymes, including PARP1, PARP5A (TNKS), PARP7 (TIPARP), PARP12, PARP13 (ZC3HAV1), and PARP14. When considering only the 60 proteins predominantly ADP-ribosylated on cysteines, there was a significant (\( p = 0.012 \)) presence of proteins involved in RNA metabolism, including DDX6, HNRNPH1, NSUN2, PAIP1, PARN, PCBP1, PP2R1A, PSMB2, TNKS1BP1, and TRNT1. Taken together, our sensitive MS-based proteomics screening of ADPr provides insight into modification of non-serine residue types and may hint at specificity of certain PARP enzymes toward distinct amino acids.

### DISCUSSION

Here, we investigated the potential of Al-ETD for sensitive identification and confident localization of ADPr sites. To evaluate the ability of Al-ETD for profiling the ADP-ribosylome, we performed a comparison of ETD, EThcD, and AI-ETD at five different LP settings.

ADP-ribosylated peptides are highly labile when subjected to collisional activation, with the ADP-ribose itself presenting the lowest energy pathway for vibrational energy redistribution (Bensiglio et al., 2017a; Larsen et al., 2018). In contrast, ADPr peptides are very stable when subjected to ETD, and here we observed ADPr peptides to be much more prone to ETnoD, compared with unmodified peptides within the same samples. EThcD failed to completely overcome ETnoD and resulted in decreased spectral quality at higher energies. Intriguingly, we observed that ADPr peptides are highly susceptible to Al-ETD, much more so than small unmodified peptides within the same sample. This susceptibility to Al-ETD resulted in a near-complete abolishing of ETnoD at 25% LP and higher, although these greater energies also resulted in over-fragmentation of the peptides and a sharp drop in spectral quality. At a modest level of energy, Al-ETD resulted in higher quality spectra, improved sensitivity, and more confident localization of ADPr to acceptor amino acids, overall doubling the number of identifications compared with pure ETD.

Recent advances in MS-based proteomics have largely focused on high-throughput analyses, essentially by minimizing time or input material required to achieve the same depth of sequencing (Bache et al., 2018; Batth et al., 2019). Compared with relatively abundant PTMs, such as phosphorylation and glycosylation, for which MS methodology is well established (Högrebe et al., 2018; Kelsstrup et al., 2018; Riley et al., 2019), the study of ADPr with MS-based proteomics remains daunting. Using AI-ETD, we identified >500 ADPr sites from single-shot analyses of purified ADPr material originating from only ~5 million cells. Moreover, from fractionated samples originating from ~100 million cells, we identified >5,000 ADPr sites, reaching a great depth of sequencing while using considerably less starting material than other studies (Hendriks et al., 2019; Larsen et al., 2018; Leutert et al., 2018; Li et al., 2019; Martello et al., 2016; Zhang et al., 2013).

Compared with ADPr induced by oxidative stress, the identification of ADPr in unperturbed cells is exceptionally challenging, with the modification occurring at very low abundance and...
Our compilation of physiological ADPr target proteins (Table 1; Table S6) should serve as a valuable knowledge base for further investigation of the role of ADPr under endogenous and unperturbed conditions. Interestingly, we found that proteins exclusively ADP-ribosylated under physiological conditions were preferentially modified on arginine residues, and these ADPr target proteins were primarily localized to the ER and the Golgi (Figure 4B), suggesting that modification of these proteins is not mediated by PARP1 or PARP2. The ARTCs are known to catalyze arginine ADPr, and even though ARTC4 and ARTC5 were detected in a deep HeLa proteomics study (Bekker-Jensen et al., 2017), ARTC1 and ARTC3 were below the limit of detection. However, ARTC1 has been demonstrated to be localized to the ER (Fabrizio et al., 2015), and in the same study ARTC1 was shown to be expressed in HeLa cells. Therefore, we speculate that sub-stoichiometric levels of ARTC1 could be responsible for the arginine ADPr we observed to be localized to the ER and the Golgi in this study. In support of this, a recent proteomics study that profiled ADPr in heart and skeletal muscle from wild-type and ARTC1 knockout mice (Leutert et al., 2018) also demonstrated that ARTC1 is responsible for the majority of arginine ADPr. Indeed, out of the 78 proteins with physiological arginine ADPr, 31 were also detected by Leutert et al. (2018) to be modified on arginines, with 28 of these no longer detected in ARTC1-deficient mice (Table S6).

Auto-modification of PARPs is a known phenomenon (Vyas et al., 2014), with especially auto-modification of PARP1 being thoroughly studied (Chapman et al., 2013; Muthurajan et al., 2014). Here, we provide evidence that ADPr occurs on PARP1, PARP2, PARP8, PARP12, and PARP14. For PARP1 and PARP2, serine was the main acceptor residue. This is consistent with PARP1 and PARP2 catalyzing ADPr of serine residues upon oxidative stress, in combination with HPF1 (Bonfiglio et al., 2017b; Larsen et al., 2018; Palazzo et al., 2018). Although we observed a relatively high number of serine residues being ADP-ribosylated under physiological conditions, many of those were also detectable in response to oxidative stress. In contrast, ADPr sites exclusively detected under physiological conditions were only rarely modifying serine residues. Taken together, this suggests that serine ADPr observed under physiological conditions could be a result of baseline DNA damage, potentially as a consequence of culturing cells under atmospheric oxygen conditions.

Intriguingly, we observed PARP8 to be ADP-ribosylated only on cysteine residues. This exclusive modification of cysteine residues supports previous in vitro observations of the auto-modification of PARP8 (Vyas et al., 2014), and we confirmed all four hitherto reported cysteine residues, of which three were detectable under physiological conditions. In the case of PARP14, physiological ADPr targeted only tyrosine residues, similarly setting it apart from PARP1 and PARP2, which were primarily modified on serine residues. Auto-modification of PARP14 has been described previously (Qin et al., 2019), and the interactome of PARP14 suggests a role in regulating RNA stability (Carter-O’Connell et al., 2018). Furthermore, PARP14 plays a critical role in innate immunity by preventing ADPr-mediated inhibition of coronavirus replication (Grunewald et al., 2019). Thus, insight into physiological and site-specific PARP14 ADPr may aid in further understanding the functional role that PARP14 plays in the interferon response and RNA metabolism. Overall, the auto-modification of PARP8 and PARP14 could suggest that these enzymes may have the ability to specifically ADP-ribosylate cysteine and tyrosine residues, respectively. However, further investigation is required to elucidate whether, and how, such specificity would be mediated.

Taken together, the combination of the AI-ETD technology with our Af1521 strategy for unbiased purification of ADPr peptides has culminated in a highly sensitive MS-based proteomics approach that can confidently identify large numbers of ADPr events from limited starting material. Moreover, this increased sensitivity makes it feasible to profile ADPr in an entirely physiological context, taking a final step toward biomedical and clinical applicability.

STAR+METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead Contact
  - Materials Availability
  - Data and Code Availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Cell lines
  - Bacteria
- METHOD DETAILS
  - Cell treatment
  - Cell lysis and protein digestion
  - Purification of ADP-ribosylated peptides
  - Mass spectrometric analysis
  - Data analysis
  - Data filtering
  - Determination of fragmentation efficiency
  - Comparison to other studies
- QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.celrep.2020.108176.

ACKNOWLEDGMENTS

The work carried out in this study was in part supported by the Novo Nordisk Foundation Center for Protein Research, the Novo Nordisk Foundation (grant...
agreement numbers NFN14CC0001 and NFN13OC0006477). The Danish Council of Independent Research (grant agreement numbers 4002-00051, 4183-00322A, 8020-0220B, and 0135-00096B), and The Danish Cancer Society (grant agreement R146-A9159-16-S2). B.F. is the recipient of a fellowship from the Novo Nordisk Foundation as part of the Copenhagen Bioscience PhD Programme (grant agreement number NFN19SA003542). The AI-ETD technology was funded by the National Institutes of Health-supported National Center for Quantitative Biology of Complex Systems (P41GM108538). The proteomics technology applied was part of a project that has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement EPIC-XS-823839. We would like to acknowledge the lab of Michael O. Hottiger for the expression and purification of recombinant human PARG (University of Zurich), and we thank members of the NFN-CPR Mass Spectrometry Platform for instrument support and technical assistance.

AUTHOR CONTRIBUTIONS

DECLARATION OF INTERESTS
The authors declare no competing interests.

Received: February 21, 2020
Revised: May 25, 2020
Accepted: August 31, 2020
Published: September 22, 2020

REFERENCES


STAR METHODS

KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bacterial and Virus Strains</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BL21(DE3)</td>
<td>New England BioLabs</td>
<td>Cat#C25271</td>
</tr>
<tr>
<td><strong>Chemicals, Peptides, and Recombinant Proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrogen peroxide (H2O2)</td>
<td>Sigma Aldrich</td>
<td>Cat#H1009</td>
</tr>
<tr>
<td>Lysyl Endopeptidase (Lys-C)</td>
<td>Wako Chemicals</td>
<td>Cat#129-02541</td>
</tr>
<tr>
<td>Trypsin, Proteomics Grade</td>
<td>Sigma Aldrich</td>
<td>Cat#T6567</td>
</tr>
<tr>
<td>Recombinant PARG enzyme</td>
<td>Prof. Dr. Michael O. Hottiger</td>
<td>N/A</td>
</tr>
<tr>
<td>Recombinant GST-tagged Af1521</td>
<td>Martello et al., 2016</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Deposited Data</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raw and analyzed ADP-ribosylation MS data</td>
<td>This paper</td>
<td>ProteomeXchange: PXD017417</td>
</tr>
<tr>
<td><strong>Experimental Models: Cell Lines</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HeLa</td>
<td>ATCC</td>
<td>CCL-2</td>
</tr>
</tbody>
</table>

RESOURCE AVAILABILITY

**Lead Contact**
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Michael Lund Nielsen (michael.lund.nielsen@cpr.ku.dk).

**Materials Availability**
This study did not generate new unique reagents.

**Data and Code Availability**
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2019) partner repository with the dataset identifier PXD017417.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

**Cell lines**
HeLa cells (CCL-2, female) were acquired via the American Type Culture Collection, and cultured at 37°C and 5% CO2 in Dulbecco’s Modified Eagle’s Medium (Invitrogen) supplemented with 10% fetal bovine serum and a penicillin/streptomycin mixture (100 U/mL; GibCO). Cells were routinely tested for mycoplasma. Cells were not routinely authenticated.

**Bacteria**
BL21(DE3) Competent E.coli were acquired from New England BioLabs. Details regarding culture conditions were reported previously (Larsen et al., 2018).

METHOD DETAILS

**Cell treatment**
For initial optimization and benchmarking experiments, ADP-ribosylation was induced in HeLa by treatment of the cells with 1 mM H2O2 (Sigma Aldrich) for 10 min in PBS at 37°C. Five cell culture replicates were prepared, each corresponding to approximately 100 million HeLa cells, of which one was used for optimization, and four for benchmarking. For physiological experiments, cells were left untreated, and four cell culture replicates were prepared, each corresponding to approximately 100 million HeLa cells.

**Cell lysis and protein digestion**
The full procedure for enrichment of ADPr from cells was done as described previously (Hendriks et al., 2019; Larsen et al., 2018). Briefly, cells were washed twice with ice-cold PBS, and gently scraped at 4°C in a minimal volume of PBS. Cells were pelleted by...
centrifugation at 500g, and lysed in 10 pellet volumes of Lysis Buffer (6 M guanidine-HCl, 50 mM TRIS, pH 8.5). Complete lysis was achieved by alternating vigorous shaking with vigorous vortexing, for 30 s, prior to snap freezing of the lysates using liquid nitrogen. Frozen lysates were stored at –80°C until further processing. Lysates were thawed and sonicated at 30 W, for 1 s per 1 mL of lysate, spread across 3 separate pulses. Tris(2-carboxyethyl)phosphine and chloroacetamide were added to a final concentration of 5 mM, and the lysate was incubated for 1 h at 30°C. Proteins were digested using Lysyl Endopeptidase (Lys-C, 1:100 w/w; Wako Chemicals) for 3 hours, and diluted with three volumes of 50 mM ammonium bicarbonate. Half of the samples was further digested overnight using modified sequencing grade Trypsin (1:200 w/w, Sigma Aldrich), and the other half was re-digested overnight using Lys-C. Digested samples were acidified by addition of trifluoroacetic acid (TFA) to a final concentration of 0.5% (v/v), cleared by centrifugation, and purified using reversed-phase C18 cartridges (SepPak Classic, 360 mg sorbent, Waters) according to the manufacturer’s instructions. Elution of peptides was performed with 30% or 40% ACN in 0.1% TFA, for peptides digested with either trypsin or Lys-C, respectively. Eluted peptides were frozen overnight at –80°C, and lyophilized.

Purification of ADP-ribosylated peptides
GST-tagged Af1521 macrodomain was produced in-house using BL21(DE3) bacteria, and coupled to glutathione Sepharose 4B beads (Sigma-Aldrich), essentially as described previously (Hendriks et al., 2019; Larsen et al., 2018). Lyophilized peptides were dissolved in IP buffer (50 mM TRIS pH 8.0, 1 mM MgCl₂, 250 µM DTT, and 50 mM NaCl), after which long ADP-ribose polymers were reduced to monomers using recombinant PARG at a concentration of 1:10,000 (w/w), overnight and at room temperature. Subsequently, 100 µL of Sepharose beads with GST-tagged Af1521 were added to the samples, and mixed at 4°C for 3 h. Beads were sequentially washed four times with ice-cold Buffer A, twice with ice-cold PBS, and two times with ice-cold MQ water. On the first wash, beads were transferred to 1.5 mL LoBind tubes (Eppendorf), and LoBind tubes were exclusively used from this point on to minimize loss of peptide. Additional tube changes were performed every second washing step to minimize carryover of background. ADP-ribosylated peptides were removed from the beads using two elution steps with 200 µL ice-cold 0.15% TFA, and the pooled elutions were throughput cleared through 0.45 µm spin filters (Ultrafree-MC, Millipore) and subsequently through pre-washed 100 kDa cut-off filters (Vivaco 500, Sartorius). The filtered ADP-ribosylated peptides were purified using C18 StageTips at high pH (Hendriks et al., 2019), and eluted either as single shot samples (optimization and physiological experiments), or eluted as seven fractions (benchmarking experiments). Briefly, samples were basified by adding ammonium solution to a final concentration of 20 mM, and loaded onto StageTips carrying four layers of C18 disc material (punch-outs from 47mm C18 3M extraction discs, Empore). Elution was performed with 25% of acetonitrile (ACN) in 20 mM ammonium hydroxide for single shot samples, or sequentially performed with 2% (F1), 4% (F2), 7% (F3), 10% (F4), 15% (F5), and 25% (F6) of ACN in 20 mM ammonium hydroxide for fractionated samples. The seven fraction (F0) was prepared by performing StageTip purification at low pH on the flowthrough fraction from sample loading at high pH. All samples were completely dried using a SpeedVac at 60°C, and dissolved in a small volume of 0.1% formic acid. Final samples were frozen at –20°C until measurement.

Mass spectrometric analysis
All MS samples were analyzed using a Fusion Lumos Orbitrap mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA) modified for AI-ETD, coupled to a Dionex UltiMate 3000 nano-UHPLC system (Thermo Fisher, Sunnyvale, CA, USA). For AI-ETD implementation, a Firestar T-100 Synrad 60 Watt (W) CO₂ continuous wave laser (Mukilteo, WA, USA) was mounted at the back of the instrument. The IR photon beam was guided into the traps using focusing lenses and a multi-mode hollow-core fiber (Opto-Knowledge Systems, Torrance, CA, USA) prior to a zinc selenide window that was placed in the vacuum manifold. Chromatographic separation of peptides was performed on a 30-cm long analytical column, with an internal diameter of 1.7 µm, packed in-house as described previously (Shishkova et al., 2018) using 130 Å pore size Bridged Ethylene Hybrid C18 particles (Waters, Milford, USA). The analytical column was heated to 50°C using an in-house made column oven. Peptides were eluted from the column using a gradient of Buffer A (0.1% formic acid) and Buffer B (80% ACN in 0.1% formic acid). The primary gradient ranged from 3% buffer B to 24% buffer B over 50 minutes, preceded by sample loading time (5 minutes for evaluation experiments, 20 minutes for benchmarking and physiological experiments), and followed by a 20 minute washing block. Electrospray ionization (ESI) was achieved using a Nanospray Flex Ion Source (Thermo). Spray voltage was set to 2.25 kV, capillary temperature to 275°C, RF level to 30%. Full MS scans were performed at resolution of 60,000, with a scan range of 300 to 1,750 m/z, a maximum injection time of 60 ms, and an automatic gain control (AGC) target of 600,000 charges. Precursors were isolated with a width of 1.3 m/z, with an AGC target of 200,000 charges, and precursor fragmentation was accomplished using either electron transfer dissociation (ETD), electron transfer dissociation with supplemental higher-collisional dissociation (EThCD) at an NCE of 20, or activated-ion electron transfer dissociation (Al-ETD); all using calibrated charge-dependent ETD parameters (Rose et al., 2015). The laser powers were the percentage of power (W) from the Firestar T-100 Synrad 60-W CO₂, continuous wave laser. For Al-ETD evaluation, laser power settings of 10% (6 W), 15% (9 W), 20% (12 W), 25% (15 W), and 30% (18 W) were used, and for benchmarking and physiological experiments a laser power setting of 20% was used. Precursors with charge state 2-5 were isolated for MS/MS analysis, and prioritized from charge 3 (highest), to 4, to 5, to 2 (lowest), using the decision tree algorithm. For benchmarking and physiological experiments, only precursors with charge state 3-5 were isolated. Precursors were excluded from repeated sequencing by setting a dynamic exclusion time of 75 s for evaluation experiments, and 90 s for benchmarking and physiological experiments, with an exclusion mass tolerance of 10 ppm. MS/MS spectra were measured in the Orbitrap, with 5 data-dependent MS/MS scans per full MS scan, a maximum precursor...
injection time of 120 ms, and a scan resolution of 60,000. First mass for MS/MS scans was set to 100 for ETD and EThcD measurements, and variable for Al-ETD measurements, with the first mass defining the laser power applied. MS/MS first masses for Al-ETD were 141, 131, 142, 132, and 143, corresponding to application of laser powers 10%, 15%, 20%, 25%, and 30%, respectively.

Data analysis
Analysis of the mass spectrometry raw data was performed using MaxQuant software (version 1.5.3.30). MaxQuant default settings were used, with exceptions outlined below. Two separate computational searches were performed, one for evaluation and physiological data, and the other for benchmarking data. For generation of the theoretical spectral library, a HUMAN.fasta database was extracted from UniProt on the 24th of May, 2019. N-terminal acetylation, methionine oxidation, cysteine carbamidomethylation, and ADP-ribosylation on all amino acid residues known to potentially be modified (C, D, E, H, K, R, S, T, and Y), were included as variable modifications. For analysis of trypsin samples, up to 6 missed cleavages were allowed. For analysis of Lys-C samples, up to 3 missed cleavages were allowed. A maximum allowance of 4 variable modifications per peptide was used. Second peptide search was enabled (default), and matching between runs was enabled with a match time window of 42 s and an alignment time window of 20 minutes. Mass tolerance for precursors was set to 20 ppm in the first MS/MS search and 4.5 ppm in the main MS/MS search after mass recalibration. For fragment ion masses, a tolerance of 20 ppm was used. Modified peptides were filtered to have an Andromeda score of > 40 (default), and a delta score of > 20. Data was automatically filtered by posterior error probability to achieve a false discovery rate of < 1% (default), at the peptide-spectrum match, the protein assignment, and the site-specific levels.

Data filtering
Beyond automatic filtering and FDR control as applied by MaxQuant, the data was manually filtered in order to ensure proper identification and localization of ADP-ribose. PSMs modified by more than one ADP-ribose were omitted. PSMs corresponding to unique peptides were only used for ADP-ribosylation site assignment if localization probability was > 0.90, with localization of > 0.75 accepted only for purposes of intensity assignment of further evidences. Erroneous MaxQuant intensity assignments were manually corrected in the sites table, and based on localized PSMs only (> 0.90 best-case, > 0.75 for further evidences). For the ADP-ribosylation target proteins table, the proteinGroups.txt file generated by MaxQuant was filtered to only contain those proteins with at least one ADP-ribosylation site detected and localized post-filtering as outlined above, with cumulative ADP-ribosylation site intensities based only on localized evidences.

Determination of fragmentation efficiency
An in-house Python script was used to determine the intensities of non-reduced precursors (no ETD), and the corresponding non-dissociated charge-reduced precursor ions (ETnoD) for each MS/MS spectrum. For that, the centroided, de-isotoped, and charge-deconvoluted peak lists from the MaxQuant Andromeda Peak List (APL) files were used. Second peptide search APLs were not considered. “No ETD” precursor peaks were expected at:

\[ m/z = \text{Precursor}_{m/z} \times \text{Charge} - \text{Charge} + 1 \]

“ETnoD” peaks were expected at:

\[ \text{ETnoD}_{m/z} = \text{Precursor}_{m/z} \times \text{Charge} - (0, 1, \ldots, \text{Charge} - 2) \]

This compensates for MaxQuant charge deconvolution, which goes by the assumption that the charge state is purely dependent on added protons. The expected peaks were matched to peaks from the MaxQuant APL files, with a mass tolerance of 0.05 Da, and their intensities were stored. Intensity information was mapped to the msms.txt output file from MaxQuant using the scan number. Total fragmentation of peptides was calculated by division of fragment product ion intensities with the sum of all peak intensities.

Comparison to other studies
Data from other studies was retrieved from several publications and online databases. For ADP-ribosylation sites; Larsen et al. (2018), Hendriks et al. (2019), Bonfiglio et al. (2017b), Bilan et al. (2017), Leslie Pedrioli et al. (2018). For ADP-ribosylation proteins; Zhang et al. (2013), Jungmichel et al. (2013), Martello et al. (2016), Bilan et al. (2017), Larsen et al. (2018), Hendriks et al. (2019). For total proteome; Bekker-Jensen et al. (2017). For comparison of proteins between studies, all protein identifiers were mapped to the human proteome as downloaded from Uniprot on the 24th of May, 2019. In case data sources did not include Uniprot IDs, ID mapping on Uniprot was used to convert other IDs to Uniprot IDs, and otherwise gene names were used. Non-existent, non-human, and redundant entries, were discarded from the analysis. For comparison of sites between studies, all parent proteins were mapped to Uniprot IDs as described above, and afterward the reported positions of modification were used to extract 51 amino acid sequence windows (modified residue ± 25 amino acids), with the sequence windows ultimately used to directly compare identified sites. Sites mapping to non-existent, non-human, or redundant proteins, were discarded. Sites not correctly aligning to the reported amino acid residues were discarded.
QUANTIFICATION AND STATISTICAL ANALYSIS

Details regarding the statistical analysis can be found in the respective figure legends. Statistical handling of the data was primarily performed using the freely available Perseus software (Tyanova et al., 2016), and includes term enrichment analysis through FDR-controlled Fisher Exact testing, and density estimation for highly populated scatterplots. Protein Gene Ontology annotations and UniProt keywords used for term enrichment analysis were concomitantly downloaded from UniProt with the HUMAN.fasta file used for searching the RAW data. Boxplots and violin plots were generated using the BoxPlotR web tool (Spitzer et al., 2014). The online STRING database (version 11) was used for generation of protein interaction networks (Szklarczyk et al., 2017), and Cytoscape (version 3.7.1) was used for manual annotation and visualization of the STRING networks (Shannon et al., 2003).